by William Crews, MD Red blood cell genotyping predicts the antigen phenotype of the red cell by analyzing the portion of DNA that codes for red cell proteins/antigens. Carter BloodCare has performed red cell genotype testing for 10 years. Initially we used this testing to phenotype blood donors to increase our “rare unit” inventory. Over
Read more

by Laurie J Sutor, MD, MBA The 31st edition of AABB Standards for Blood Banks and Transfusion Services went into effect on April 1, 2018. There were several changes and additions of note, a few of which are of interest to hospital blood banks. Selected changes are highlighted below. Note that this article does not
Read more

by Lesley Kresie, MD The number of patients requiring a kidney transplant continues to rise each year and the number of organ donors remains insufficient to meet the need. The growing list of patients waiting for an organ has led transplant programs to look at all possible donor options for their patients, such as living
Read more

Carter BloodCare is honored to be a finalist for the D CEO’s 2018 Nonprofit and Corporate Citizenship Awards. There are many deserving finalists in the Organization of the Year category. D CEO and Communities Foundation of Texas are honoring professionals and organizations in the nonprofit world that make a positive impact on the community. They are also honoring
Read more

Confusion frequently arises over the different notifications received from a blood center regarding blood components under suspicion. This video will attempt to clarify the differences between quarantines, recalls, market withdrawals and lookbacks, the different categories of notification.

by L. Sutor, M.D., MBA, Vice President of Medical and Technical Services, Carter BloodCare Confusion frequently arises over the different notifications received from the blood center regarding blood components under suspicion. This article will attempt to clarify the differences between quarantines, market withdrawals, recalls, and lookbacks, the different categories of notification. Quarantine notifications are a preliminary notification,
Read more

by G. Paranjape, M.D., Medical Director of Clinical Services, Carter BloodCare Carter BloodCare used to perform quality control of apheresis platelets for bacteria by using a test called eBDS. This test allowed us to have a Pass/Fail (acceptable/not acceptable) result on day two and we only sent bacterially negative, or acceptable, products out to our hospitals.
Read more

If you have Heredity Hemochromatosis or Erythrocytosis/Polycythemia due to testosterone therapy, your physician may recommend blood donation as part of your treatment.  Carter BloodCare has received variances from our regulatory agency, the Food and Drug Administration to provide therapeutic phlebotomy programs for these two medical conditions.   Watch this video to understand the simple enrollment process.

If you have a patient that can benefit from therapeutic phlebotomy consider sending them to Carter BloodCare. To begin the process, follow the steps in this video.

A step-by-step instructional video on how to complete the Carter BloodCare Crossmatch Account Services Request form.